Q3 2024 saw 13% sales growth and strong results in Assistive Tech and MedTech, while Specialty Pharma declined due to UK price pressure. Acquisitions and a robust balance sheet support continued M&A activity.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.